Nalmefene auto‐injector approved for opioid overdose

This month, the U.S. Food and Drug Administration (FDA) approved Zurnia, the first nalmefene hydrochloride auto‐injector for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients ages 12 and older. The agency approved the first nasal spray formulation of nalmefene in May 2023 (see ADAW https://onlinelibrary.wiley.com/doi/10.1002/adaw.34062 ).